Sagespring Wealth Partners LLC Acquires 5,172 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sagespring Wealth Partners LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 96.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,552 shares of the medical device company's stock after acquiring an additional 5,172 shares during the period. Sagespring Wealth Partners LLC's holdings in DexCom were worth $721,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Private Trust Co. NA raised its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC raised its stake in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter worth $38,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on DXCM. Canaccord Genuity Group lifted their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group assumed coverage on shares of DexCom in a research report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target on the stock. Citigroup reiterated a "buy" rating and issued a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Barclays lifted their price target on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $98.50.

DexCom Stock Down 1.4%

Shares of NASDAQ:DXCM opened at $81.83 on Wednesday. The firm has a fifty day moving average of $79.25 and a 200 day moving average of $79.38. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.49. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market capitalization of $32.09 billion, a PE ratio of 61.07, a price-to-earnings-growth ratio of 1.77 and a beta of 1.46.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 earnings per share. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In related news, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares in the company, valued at $9,329,843.31. This represents a 5.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Nicholas Augustinos sold 2,618 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $81.69, for a total transaction of $213,864.42. Following the sale, the director now directly owns 37,083 shares of the company's stock, valued at $3,029,310.27. The trade was a 6.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,474 shares of company stock valued at $1,887,026. Corporate insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.